APO-OLMESARTAN HCTZ 20/12.5 olmesartan medoxomil/hydrochlorothiazide 20/12.5 mg film coated tablets blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

apo-olmesartan hctz 20/12.5 olmesartan medoxomil/hydrochlorothiazide 20/12.5 mg film coated tablets blister pack

arrotex pharmaceuticals pty ltd - hydrochlorothiazide, quantity: 12.5 mg; olmesartan medoxomil, quantity: 20 mg - tablet, film coated - excipient ingredients: hyprolose; magnesium stearate; lactose monohydrate; hypromellose; microcrystalline cellulose; purified water; titanium dioxide; iron oxide yellow; macrogol 4000 - indicated for the treatment of hypertension.,treatment should not be initiated with this fixed dose combination.

AVAPRO HCT 300/12.5 irbesartan 300 mg and hydrochlorothiazide 12.5 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

avapro hct 300/12.5 irbesartan 300 mg and hydrochlorothiazide 12.5 mg tablet blister pack

sanofi-aventis australia pty ltd - hydrochlorothiazide, quantity: 12.5 mg; irbesartan, quantity: 300 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; silicon dioxide; croscarmellose sodium; hypromellose; carnauba wax; magnesium stearate; lactose monohydrate; titanium dioxide; iron oxide yellow; iron oxide red; macrogol 3000 - avapro hct is indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

AVAPRO HCT 150/12.5 irbesartan 150 mg and hydrochlorothiazide 12.5 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

avapro hct 150/12.5 irbesartan 150 mg and hydrochlorothiazide 12.5 mg tablet blister pack

sanofi-aventis australia pty ltd - hydrochlorothiazide, quantity: 12.5 mg; irbesartan, quantity: 150 mg - tablet, film coated - excipient ingredients: carnauba wax; lactose monohydrate; magnesium stearate; hypromellose; croscarmellose sodium; silicon dioxide; microcrystalline cellulose; titanium dioxide; iron oxide yellow; iron oxide red; macrogol 3000 - avapro hct is indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

KARVEZIDE 300/12.5 irbesartan 300 mg and hydrochlorothiazide 12.5 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

karvezide 300/12.5 irbesartan 300 mg and hydrochlorothiazide 12.5 mg tablet blister pack

sanofi-aventis australia pty ltd - hydrochlorothiazide, quantity: 12.5 mg; irbesartan, quantity: 300 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; hypromellose; lactose monohydrate; silicon dioxide; croscarmellose sodium; magnesium stearate; carnauba wax; titanium dioxide; iron oxide yellow; iron oxide red; macrogol 3000 - karvezide is indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

KARVEZIDE 150/12.5 irbesartan 150 mg and hydrochlorothiazide 12.5 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

karvezide 150/12.5 irbesartan 150 mg and hydrochlorothiazide 12.5 mg tablet blister pack

sanofi-aventis australia pty ltd - hydrochlorothiazide, quantity: 12.5 mg; irbesartan, quantity: 150 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; carnauba wax; magnesium stearate; silicon dioxide; microcrystalline cellulose; hypromellose; lactose monohydrate; titanium dioxide; iron oxide yellow; iron oxide red; macrogol 3000 - karvezide is indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Amlodipine/Valsartan/Hydrochlorothiazide Krka 5 mg - 160 mg - 12,5 mg film-coat. tabl. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

amlodipine/valsartan/hydrochlorothiazide krka 5 mg - 160 mg - 12,5 mg film-coat. tabl.

krka d.d. novo mesto d.d. - valsartan 160 mg; amlodipine besilate 6,94 mg - eq. amlodipine 5 mg; hydrochlorothiazide 12,5 mg - film-coated tablet - 5 mg - 160 mg - 12,5 mg - amlodipine besilate 6.94 mg; valsartan 160 mg; hydrochlorothiazide 12.5 mg - valsartan, amlodipine and hydrochlorothiazide

Amlodipine/Valsartan/Hydrochlorothiazide Krka 10 mg - 160 mg - 12,5 mg film-coat. tabl. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

amlodipine/valsartan/hydrochlorothiazide krka 10 mg - 160 mg - 12,5 mg film-coat. tabl.

krka d.d. novo mesto d.d. - valsartan 160 mg; amlodipine besilate 13,88 mg - eq. amlodipine 10 mg; hydrochlorothiazide 12,5 mg - film-coated tablet - 10 mg - 160 mg - 12,5 mg - hydrochlorothiazide 12.5 mg; valsartan 160 mg; amlodipine besilate 13.88 mg - valsartan, amlodipine and hydrochlorothiazide

CANDESARTAN/HCT SANDOZ 32/12.5mg candesartan cilexetil/hydrochlorothiazide 32mg/12.5mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

candesartan/hct sandoz 32/12.5mg candesartan cilexetil/hydrochlorothiazide 32mg/12.5mg tablet bottle

sandoz pty ltd - candesartan cilexetil, quantity: 32 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet - excipient ingredients: povidone; iron oxide red; iron oxide black; croscarmellose sodium; maize starch; lactose monohydrate; magnesium stearate; carrageenan; iron oxide yellow - the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

HYDROCHLOROTHIAZIDE- hydrochlorothiazide capsule United States - English - NLM (National Library of Medicine)

hydrochlorothiazide- hydrochlorothiazide capsule

west-ward pharmaceutical corp - hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - hydrochlorothiazide 12.5 mg - hydrochlorothiazide capsules are indicated in the management of hypertension either as the sole therapeutic agent, or in combination with other antihypertensives. unlike potassium sparing combination diuretic products, hydrochlorothiazide capsules may be used in those patients in whom the development of hyperkalemia cannot be risked, including patients taking ace inhibitors. the routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. diuretics are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy. dependent edema in pregnancy resulting from restriction of venous return by the expanded uterus is properly tre

HYDROCHLOROTHIAZIDE- hydrochlorothiazide capsule United States - English - NLM (National Library of Medicine)

hydrochlorothiazide- hydrochlorothiazide capsule

heritage pharmaceuticals inc. - hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - hydrochlorothiazide 12.5 mg - hydrochlorothiazide capsules are indicated in the management of hypertension either as the sole therapeutic agent, or in combination with other antihypertensives. unlike potassium sparing combination diuretic products, hydrochlorothiazide capsules may be used in those patients in whom the development of hyperkalemia cannot be risked, including patients taking ace inhibitors. usage in pregnancy: the routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. diuretics are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy. dependent edema in pregnancy resulting from restriction of venous return by the expanded u